Prodrugs of 2,4-pyrimidinediamine compounds and their uses

Patent metadata

Field	Value
Publication number	US-9737554-B2
Application number	US-201615005771-A
Country	US
Kind code	B2
Filing date	Jan 25, 2016
Priority date	Nov 21, 2006
Publication date	Aug 22, 2017
Grant date	Aug 22, 2017

Abstract

The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.

First claim

The invention claimed is:

1. An oral dosage formulation comprising a hydrate of the prodrug salt:

or a pharmaceutically-acceptable carrier, excipient, and/or diluent; wherein:
M is Na;
the prodrug salt hydrate present in the oral dosage formulation is substantially crystalline prodrug salt hydrate; and
the powder X-ray diffraction data of the crystalline prodrug salt hydrate comprises a characteristic peak at a two theta value of 9.9±0.1° in response to radiation of wavelength 1.54059 Å.

2. The oral dosage formulation of claim 1 , the formulation comprising from about 50 mg to about 400 mg of the crystalline prodrug salt hydrate.

3. The oral dosage formulation of claim 1 , wherein the powder X-ray diffraction data of the crystalline prodrug salt hydrate comprises a characteristic peak at a two theta value of 11.8±0.1°.

4. The oral dosage formulation of claim 1 , wherein the powder X-ray diffraction data of the crystalline prodrug salt hydrate comprises a characteristic peak at a two theta value of 21.8±0.1°.

5. The oral dosage formulation of claim 1 , wherein the powder X-ray diffraction data of the crystalline prodrug salt hydrate comprises a characteristic peak at a two theta value of 13.2°±0.1°.

6. The oral dosage formulation of claim 1 , wherein the hydrate of the prodrug salt has the formula:

wherein x is from about 1 to about 15.

7. The oral dosage formulation of claim 6 , wherein x is from about 5 to about 10.

8. The oral dosage formulation of claim 6 , wherein x is from about 5 to about 8.

9. The oral dosage formulation of claim 6 , wherein x is 6.

10. The oral dosage formulation of claim 8 , wherein the powder X-ray diffraction data of the crystalline prodrug salt hydrate comprises a characteristic peak at a two theta value of 3.4°±0.1°.

11. The oral dosage formulation of claim 1 , wherein the hydrate is:

Assignees

• Rigel Pharmaceuticals Inc

Inventors

• Bhamidipati Somasekhar
• Singh Rajinder
• Sun Thomas
• Masuda Esteban

Classifications

• A61P5/16

  for decreasing, blocking or antagonising the activity of the thyroid hormones · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61P7/06

  Antianaemics · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title